Drug trial offers hope to patients with advanced colorectal cancer
A new drug treatment could offer hope to patients with advanced colorectal cancer who were intolerant of or did not respond to standard treatments, according to an article published in the Lancet Oncology.
The drug – called TAS-102 – was tested on 169 patients in Japan with inoperable, metastatic (spreading) colorectal cancer. The patients had already undergone several rounds of standard chemotherapy, to no effect, or were intolerant of standard drug treatments (which include irinotecan, oxaliplatin, and a group of drugs known as fluoropyrimidines).
Researchers found that, compared to placebo, patients treated with TAS-102 experienced improved survival time, reduced risk of death and better overall disease control, leading to hopes that the drug might one day be used as an effective treatment for advanced inoperable colorectal cancer.
Patients who received TAS-102 had a median overall survival of 9 months, as compared to 6.6 months for the placebo group. The TAS-102 group were also 44% less likely to die during the trial period than those given placebo.
Importantly, TAS-102 appears to be relatively safe, being well tolerated by most patients. While some patients experienced adverse reactions to the drug (mostly blood disorders), in all cases they were able to resume treatment after the blood disorder had been addressed.
Colorectal cancer accounts for around 10% of all cancer cases, and is the fourth-leading cause of cancer-related deaths worldwide. There are currently no clinically proven treatment options available for patients with advanced, inoperable colorectal cancer who do not respond to, or are intolerant of, the standard drug treatments for the disease.
According to lead author Dr Takayuki Yoshino, of the National Cancer Center Hospital East in Kashiwa, Chiba, Japan, "Treatments that confer a survival benefit in patients with heavily pretreated metastatic colorectal cancer are urgently needed. Our results show that TAS-102 has a promising efficacy and an easily manageable safety profile for a group of patients who have virtually no other treatment options available to them."
In a linked Comment, Dr Alberto Sobrero of the Ospedale San Martino in Genoa, Italy, welcomes the results, while emphasising that further work will be needed to confirm the results, adding that "With the assumption that the results represent the true effect of TAS-102, a new important advance in the treatment of colorectal cancer will have been made."
More information: www.thelancet.com/… 5-5/abstract
Journal reference: Lancet Oncology
Provided by Lancet
- Drug improves survival of colorectal cancer patients, trial results show Jan 18, 2012 | not rated yet | 0
- Chemotherapy and radiation given together could help elderly patients with lung cancer live longer May 21, 2012 | not rated yet | 0
- Cetuximab did not add significant benefit to NORDIC FLOX regimen in first line treatment of mCRC Oct 12, 2010 | not rated yet | 0
- Merck KGaA suffers setback on cancer drug Jul 05, 2012 | not rated yet | 0
- Surgical treatment provides new option for some colorectal cancer patients Sep 30, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
Cancer 22 hours ago | not rated yet | 0
Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.
Cancer 23 hours ago | not rated yet | 1
A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...
Cancer May 18, 2013 | 5 / 5 (2) | 0
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer May 17, 2013 | not rated yet | 0
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer May 17, 2013 | not rated yet | 0 |
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
10 hours ago | not rated yet | 0 |
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
11 hours ago | 4.8 / 5 (4) | 0 |
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
11 hours ago | 5 / 5 (2) | 0 |
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
10 hours ago | 5 / 5 (2) | 0 |
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
15 hours ago | not rated yet | 0
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
10 hours ago | not rated yet | 0